The link between cutaneous inflammation and cognitive impairment

Cognitive impairment is a symptom of neurological disorders, including dementia and Alzheimer's disease; and mild cognitive impairment can be a precursor of both disorders. Aged humans and animal models with other systemic disorders, such as cardiovascular diseases and diabetes, display a highe...

Full description

Saved in:
Bibliographic Details
Published inJournal of the European Academy of Dermatology and Venereology Vol. 36; no. 10; pp. 1705 - 1712
Main Authors Wen, S., Elias, P.M., Wakefield, J.S., Mauro, T.M., Man, M.‐Q.
Format Journal Article
LanguageEnglish
Published 01.10.2022
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cognitive impairment is a symptom of neurological disorders, including dementia and Alzheimer's disease; and mild cognitive impairment can be a precursor of both disorders. Aged humans and animal models with other systemic disorders, such as cardiovascular diseases and diabetes, display a higher incidence of cognitive decline. Epidemiological studies have shown that the incidence of cognitive impairment also is higher in subjects with certain inflammatory skin disorders, including psoriasis and chronic eczematous dermatitis. Chronologically aged individuals exhibit increased cutaneous inflammation and elevated circulating cytokine levels, linked to alterations in epidermal function, which itself can induce cutaneous inflammation. Conversely, strategies that improve epidermal function can lower cytokine levels in both the skin and circulation. Thus, it seems likely that epidermal dysfunction could contribute, at least in part, to the development of chronic low‐grade inflammation, also termed ‘inflammaging’, in the elderly. The evidence of cognitive impairment in patients with inflammatory dermatoses suggests a link between cutaneous inflammation and cognitive impairment. Because of the pathogenic role of epidermal dysfunction in ageing‐associated cutaneous inflammation, improvements in epidermal function could be an alternative approach for mitigation of the ageing‐associated decline in cognitive function.
Bibliography:Conflicts of interest
Funding sources
All authors declare no conflicts of interest except that Dr. Elias is a co‐inventor of EpiCeram®, licensed from the University of California to Primus Pharmaceuticals, LLC, Scottsdale, AZ.
This work was supported, in part, by NIH grant R01 AR061106, administered by the Northern California Institute for Research and Education, with resources from the Research Service, Department of Veterans Affairs Medical Center San Francisco, and by the Medical Science Foundation of Guangdong (B2020034), China. This content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Author Contributions: MMQ, conceptualization; MMQ and SW, literature search and draft; PEM and JSW, critical review and draft; TMM, critical review.
ISSN:0926-9959
1468-3083
1468-3083
DOI:10.1111/jdv.18360